MarketCap
Facebook
X
Telegram
Catalent EBITDA | CTLT
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Catalent
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -260 M | 259 M | 1.11 B | 1.12 B | 648 M | 503 M | 459 M | 381 M | 358 M | 401 M | 384 M | 357 M | 328 M | 318 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 B | -260 M | 454 M |
Quarterly EBITDA Catalent
| 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46 M | 342 M | 121 M | -614 M | 9 M | 73 M | 340 M | 159 M | 241 M | 159 M | 400 M | 489 M | 340 M | 219 M | 267 M | 585 M | 267 M | 151 M | 212 M | 95 M | 151 M | 240 M | 186 M | 73.3 M | 133 M | 211 M | 155 M | 70.9 M | 115 M | 172 M | 119 M | 60.6 M | 83.4 M | 137 M | 129 M | 60.6 M | 93.8 M | 170 M | 133 M | 72.6 M | 97.6 M | 77.5 M | 133 M | 77.5 M | 81.8 M | 71.6 M | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 585 M | -614 M | 152 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Perrigo Company plc
PRGO
|
-785 M | $ 15.85 | -0.72 % | $ 2.2 B |  USA |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Harrow Health
HROW
|
31.8 M | $ 28.95 | 1.79 % | $ 1.06 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-5.2 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
3.02 B | $ 6.36 | -1.32 % | $ 2.36 B |  Canada |
 |
OrganiGram Holdings
OGI
|
-35.7 M | $ 0.94 | 1.44 % | $ 89.6 M | Canada |
 |
Organogenesis Holdings
ORGO
|
60 M | $ 0.94 | -5.84 % | $ 119 M | USA |
 |
Pacira BioSciences
PCRX
|
110 M | $ 36.39 | -0.08 % | $ 1.62 B | USA |
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-143 M | $ 0.67 | -1.33 % | $ 200 M | Canada |
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M | USA |
 |
Rockwell Medical
RMTI
|
-2.5 M | $ 7.06 | 1.73 % | $ 254 M | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 3.8 | 0.4 % | $ 190 M | USA |
 |
Solid Biosciences
SLDB
|
-178 M | $ 5.81 | -1.94 % | $ 508 M | USA |
 |
Sundial Growers
SNDL
|
-6.35 M | $ 1.26 | -1.94 % | $ 325 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.32 M | $ 1.12 | 0.9 % | $ 1.89 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | USA |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
-63 M | $ 2.73 | -3.02 % | $ 305 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
TherapeuticsMD
TXMD
|
-4.01 M | $ 1.81 | 0.56 % | $ 20.9 M | USA |
 |
Cronos Group
CRON
|
-3.16 M | $ 3.32 | -1.04 % | $ 1.27 B | Canada |
 |
Veru
VERU
|
-24.6 M | $ 2.21 | -1.34 % | $ 32.4 M | USA |
 |
Viatris
VTRS
|
135 M | $ 18.29 | 1.67 % | $ 21 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
DURECT Corporation
DRRX
|
-18.8 M | - | - | $ 50.1 M | USA |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
OptiNose
OPTN
|
-16 M | - | - | $ 1.08 B | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Aurora Cannabis
ACB
|
4.95 M | $ 3.91 | 0.73 % | $ 214 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
2.77 M | $ 4.37 | -48.53 % | $ 64.9 M | USA |
 |
Emergent BioSolutions
EBS
|
196 M | $ 6.37 | 2.25 % | $ 341 M | USA |
 |
Evolus
EOLS
|
-25.2 M | $ 7.18 | 2.43 % | $ 463 M | USA |
 |
China Pharma Holdings
CPHI
|
-1.74 M | $ 0.63 | -1.84 % | $ 2.7 M |  China |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 3.24 | -1.07 % | $ 128 M | USA |
 |
cbdMD
YCBD
|
-1.8 M | $ 0.36 | -1.06 % | $ 1.45 M | USA |
 |
HEXO Corp.
HEXO
|
-1.07 B | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-373 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
8.47 M | - | - | $ 150 M | USA |
 |
Jupiter Wellness
JUPW
|
654 K | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-100 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
-13.2 M | - | - | $ 5.07 M | USA |